1. Home
  2. LSTA vs EVAX Comparison

LSTA vs EVAX Comparison

Compare LSTA & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lisata Therapeutics Inc.

LSTA

Lisata Therapeutics Inc.

HOLD

Current Price

$3.36

Market Cap

28.9M

Sector

Health Care

ML Signal

HOLD

EVAX

Evaxion Biotech

HOLD

Current Price

$3.09

Market Cap

30.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LSTA
EVAX
Founded
1980
2008
Country
United States
Denmark
Employees
N/A
N/A
Industry
Misc Health and Biotechnology Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
28.9M
30.4M
IPO Year
2000
2020

Fundamental Metrics

Financial Performance
Metric
LSTA
EVAX
Price
$3.36
$3.09
Analyst Decision
Buy
Strong Buy
Analyst Count
2
3
Target Price
$15.00
$11.67
AVG Volume (30 Days)
95.2K
28.5K
Earning Date
05-11-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
20.42
N/A
EPS
N/A
N/A
Revenue
$35,283,868.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$328.20
P/E Ratio
N/A
N/A
Revenue Growth
56.90
N/A
52 Week Low
$1.81
$2.28
52 Week High
$5.07
$12.15

Technical Indicators

Market Signals
Indicator
LSTA
EVAX
Relative Strength Index (RSI) 45.00 39.30
Support Level $3.06 $2.92
Resistance Level $3.41 $3.62
Average True Range (ATR) 0.13 0.29
MACD -0.01 -0.02
Stochastic Oscillator 2.86 21.91

Price Performance

Historical Comparison
LSTA
EVAX

About LSTA Lisata Therapeutics Inc.

Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.

About EVAX Evaxion Biotech

Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.

Share on Social Networks: